The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant chemotherapy and surgery for rectal cancer: Omission of radiation in clinical practice.
 
Matthew Hill
No Relationships to Disclose
 
Emma Schatoff
Stock and Other Ownership Interests - Moderna Therapeutics
 
Thikhamporn Tawantanakorn
No Relationships to Disclose
 
Mithat Gonen
Travel, Accommodations, Expenses - Genentech
 
Marc Gollub
No Relationships to Disclose
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Christopher Crane
Stock and Other Ownership Interests - Oncternal Therapeutics
Honoraria - Elekta
Consulting or Advisory Role - TriSalus Life Sciences
Research Funding - Elekta (Inst)
 
Paul Romesser
Employment - Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - EMD Serono; Faeth Therapeutics; Natera
Research Funding - X-RAD Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - Anal Cancer Foundation; HPV Alliance
 
Leonard Saltz
No Relationships to Disclose
 
Julio Garcia-Aguilar
Stock and Other Ownership Interests - Intuitive surgical
 
Andrea Cercek
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - Abbvie; Agenus; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Regeneron; Roche/Genentech; Seagen
Research Funding - GlaxoSmithKline; Seagen
Patents, Royalties, Other Intellectual Property - Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Neoadjuvant PD1 blockade in mismatch repair deficient solid tumors (Inst)
 
Martin Weiser
Patents, Royalties, Other Intellectual Property - UpToDate Section Editor